MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, TYRA had $7,568K increase in cash & cash equivalents over the period. -$32,659K in free cash flow.

Cash Flow Overview

Change in Cash
$7,568K
Free Cash flow
-$32,659K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from issuances of commo...
    • Maturities of marketable securit...
    • Proceeds from issuances of commo...
    • Others
Negative Cash Flow Breakdown
    • Purchases of marketable securiti...
    • Net loss
    • Prepaid expenses and other asset...
    • Others

Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net loss
-39,305 -33,834 -86,113 -
Depreciation
138 132 414 -
Stock-based compensation
7,847 7,627 20,379 -
Accretion of marketable securities, net
-25 -126 -1,993 -
Prepaid expenses and other assets
2,438 -404 5,484 -
Accounts payable, accrued expenses and other liabilities
1,195 2,156 1,213 -
Right-of-use assets and lease liabilities, net
17 17 66 -
Net cash used in operating activities
-32,571 -23,624 -71,518 -
Purchases of marketable securities
162,206 9,106 92,148 -
Maturities of marketable securities
42,050 43,540 130,318 -
Purchases of property and equipment
88 57 84 -
Net cash provided by (used in) investing activities
-120,244 34,377 38,086 -
Proceeds from issuances of common stock under benefit plans
12,530 4,683 3,417 -
Proceeds from issuance of common stock and pre-funded warrants from private placement
-0 0 -
Payments of issuance costs for common stock and pre-funded warrants from private placement
-0 0 -
Proceeds from issuances of common stock under at-the-market offering program, net of 2.1 million of issuance costs
147,853 ---
Net cash provided by financing activities
160,383 4,683 3,417 -
Restricted cash
---1,000
Net cash increase (decrease) for the period
7,568 15,436 -30,015 -
Cash and cash equivalents
---98,490
Cash, cash equivalents and restricted cash at beginning of the period
78,387 62,951 99,490 -
Cash, cash equivalents and restricted cash at end of the period
85,955 78,387 62,951 99,490
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuancesof common stock...$147,853K Proceeds from issuancesof common stock...$12,530K Net cash provided byfinancing activities$160,383K Net cash increase(decrease) for the period$7,568K Canceled cashflow$152,815K Maturities of marketablesecurities$42,050K Stock-based compensation$7,847K Accounts payable,accrued expenses and...$1,195K Depreciation$138K Right-of-use assets and leaseliabilities, net$17K Net cash provided by(used in) investing...-$120,244K Net cash used inoperating activities-$32,571K Canceled cashflow$42,050K Canceled cashflow$9,197K Purchases of marketablesecurities$162,206K Net loss-$39,305K Purchases of property andequipment$88K Prepaid expenses andother assets$2,438K Accretion of marketablesecurities, net-$25K

Tyra Biosciences, Inc. (TYRA)

Tyra Biosciences, Inc. (TYRA)